Nektar Therapeutics (NKTR) Change in Accured Expenses (2010 - 2026)

Nektar Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 91.44% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at -$4.7 million (down 146.14% YoY), while the FY2025 annual figure was -$5.8 million, down 153.9% from the prior year.
• Change in Accured Expenses was $2.3 million for Q1 2026 at Nektar Therapeutics, up from -$2.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $14.2 million in Q1 2022 to a low of -$21.5 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged -$1.8 million across 5 years, with a median of $412000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses plunged 770.7% in 2023, then jumped 1489.56% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$21.5 million in 2022, then surged by 54.77% to -$9.7 million in 2023, then surged by 32.45% to -$6.6 million in 2024, then surged by 58.64% to -$2.7 million in 2025, then soared by 185.42% to $2.3 million in 2026.
• The last three Change in Accured Expenses figures came in at $2.3 million (Q1 2026), -$2.7 million (Q4 2025), and -$7.0 million (Q3 2025), per Business Quant data.